ImmuronIMRN
Market Cap: $14.8M
About: Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
Employees: 6
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0.01% less ownership
Funds ownership: 0.02% [Q1] → 0.01% (-0.01%) [Q2]
43% less funds holding
Funds holding: 7 [Q1] → 4 (-3) [Q2]
73% less capital invested
Capital invested by funds: $103K [Q1] → $28.1K (-$75K) [Q2]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Research analyst outlook
We haven’t received any recent analyst ratings for IMRN.